Literature DB >> 15486323

Antiinflammatory properties of HDL.

Philip J Barter1, Stephen Nicholls, Kerry-Anne Rye, G M Anantharamaiah, Mohamad Navab, Alan M Fogelman.   

Abstract

There are several well-documented functions of high-density lipoprotein (HDL) that may explain the ability of these lipoproteins to protect against atherosclerosis. The best recognized of these is the ability of HDL to promote the efflux of cholesterol from cells. This process may minimize the accumulation of foam cells in the artery wall. However, HDL has additional properties that may also be antiatherogenic. For example, HDL is an effective antioxidant. The major proteins of HDL, apoA-I and apoA-II, as well as other proteins such as paraoxonase that cotransport with HDL in plasma, are well-known to have antioxidant properties. As a consequence, HDL has the capacity to inhibit the oxidative modification of low-density lipoprotein (LDL) in a process that reduces the atherogenicity of these lipoproteins. HDL also possesses other antiinflammatory properties. By virtue of their ability to inhibit the expression of adhesion molecules in endothelial cells, they reduce the recruitment of blood monocytes into the artery wall. These antioxidant and antiinflammatory properties of HDL may be as important as its cholesterol efflux function in terms of protecting against the development of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486323     DOI: 10.1161/01.RES.0000146094.59640.13

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  400 in total

1.  Targeted deletion of endothelial lipase increases HDL particles with anti-inflammatory properties both in vitro and in vivo.

Authors:  Tetsuya Hara; Tatsuro Ishida; Yoko Kojima; Hanayo Tanaka; Tomoyuki Yasuda; Masakazu Shinohara; Ryuji Toh; Ken-ichi Hirata
Journal:  J Lipid Res       Date:  2010-10-06       Impact factor: 5.922

2.  Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry.

Authors:  Sean A Agger; Luke C Marney; Andrew N Hoofnagle
Journal:  Clin Chem       Date:  2010-10-05       Impact factor: 8.327

3.  Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects.

Authors:  Urbain Tchoua; Corina Rosales; Daming Tang; Baiba K Gillard; Ashley Vaughan; Hu Yu Lin; Harry S Courtney; Henry J Pownall
Journal:  Lipids       Date:  2010-10-24       Impact factor: 1.880

4.  Using bioinformatics and systems genetics to dissect HDL-cholesterol genetics in an MRL/MpJ x SM/J intercross.

Authors:  Magalie S Leduc; Rachael Hageman Blair; Ricardo A Verdugo; Shirng-Wern Tsaih; Kenneth Walsh; Gary A Churchill; Beverly Paigen
Journal:  J Lipid Res       Date:  2012-04-11       Impact factor: 5.922

5.  Lipoproteins: When size really matters.

Authors:  J Bruce German; Jennifer T Smilowitz; Angela M Zivkovic
Journal:  Curr Opin Colloid Interface Sci       Date:  2006-06       Impact factor: 6.448

Review 6.  A new framework for reverse cholesterol transport: non-biliary contributions to reverse cholesterol transport.

Authors:  Ryan-E Temel; J-Mark Brown
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

7.  Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI.

Authors:  Manojkumar Valiyaveettil; Niladri Kar; Mohammad Z Ashraf; Tatiana V Byzova; Maria Febbraio; Eugene A Podrez
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

8.  Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties.

Authors:  A Hoang; A J Murphy; M T Coughlan; M C Thomas; J M Forbes; R O'Brien; M E Cooper; J P F Chin-Dusting; D Sviridov
Journal:  Diabetologia       Date:  2007-06-20       Impact factor: 10.122

9.  Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosis.

Authors:  Giorgio Cavigiolio; Shobini Jayaraman
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

10.  Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.

Authors:  Yu Kataoka; Jordan Andrews; MyNgan Duong; Tracy Nguyen; Nisha Schwarz; Jessica Fendler; Rishi Puri; Julie Butters; Constance Keyserling; John F Paolini; Jean-Louis Dasseux; Stephen J Nicholls
Journal:  Cardiovasc Diagn Ther       Date:  2017-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.